Cargando…

Application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis

BACKGROUND: To summarize the current evidence on the effects of intra-arterial chemotherapy (IAC) on high-risk non-muscle invasive bladder cancer (NMIBC) and compare oncology results with intravesical chemotherapy (IVC). METHODS: We performed a systematic review and cumulative meta-analysis of the p...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Chengyu, Li, Xianhui, Du, Yuelin, Wang, Hui, Zhang, Xiaojun, Wei, Tangqiang, Wang, Anguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485834/
https://www.ncbi.nlm.nih.gov/pubmed/34692255
http://dx.doi.org/10.7717/peerj.12248
_version_ 1784577613775241216
author You, Chengyu
Li, Xianhui
Du, Yuelin
Wang, Hui
Zhang, Xiaojun
Wei, Tangqiang
Wang, Anguo
author_facet You, Chengyu
Li, Xianhui
Du, Yuelin
Wang, Hui
Zhang, Xiaojun
Wei, Tangqiang
Wang, Anguo
author_sort You, Chengyu
collection PubMed
description BACKGROUND: To summarize the current evidence on the effects of intra-arterial chemotherapy (IAC) on high-risk non-muscle invasive bladder cancer (NMIBC) and compare oncology results with intravesical chemotherapy (IVC). METHODS: We performed a systematic review and cumulative meta-analysis of the primary outcomes of interest by a systematical search of multiple scientific databases in February 2021. The mean difference (MD) and odds ratio (OR) were calculated for continuous and dichotomous variables respectively, with 95% confidence intervals (CIs). The hazard radio (HR) with 95% CIs was used for overall survival (OS), recurrence-free survival (RFS) and progression-free survival (PFS). RESULTS: A total of six studies with 866 patients were included. For IAC combined with IVC versus IVC alone, statistically significant differences were found regarding tumor recurrence rate (OR: 0.51, 95% CI [0.36∼0.72], p = 0.0001), tumor progression rate (OR: 0.47, 95% CI [0.30∼0.72], p = 0.0006), tumor-specific death rate (OR: 0.49, 95% CI [0.25∼0.99], p = 0.05), PFS (HR: 0.47, 95% CI [0.23∼0.96], p = 0.04) and RFS (HR: 0.60, 95% CI [0.41∼0.87], p = 0.007). No significant difference between two groups was found for time to first recurrence (MD: 3.27, 95% CI [−2.37∼8.92], p = 0.26) and OS (HR: 1.20, 95% CI [0.44∼3.32], p = 0.72). For IAC alone versus IVC, There was no statistical difference in the terms of tumor-specific death rate (OR: 0.67, 95% CI [0.29∼1.53], p = 0.34), RFS (HR: 0.90, 95% CI [0.56∼1.46], p = 0.68) and PFS (HR: 0.71, 95% CI [0.32∼1.55], p = 0.39). Adverse events mainly included nausea/vomiting (36.3%), hypoleukemia (19.4%), neutropenia (16.0%), increased creatinine (9.9%), increased alanine aminotransferase (18.7%), and thrombocytopenia (9.9%). CONCLUSION: The IAC combined with IVC is a safe and effective treatment for high risk NMIBC, with lower rates of recurrence, progression, tumor-specific death, PFS and RFS, and with minor and tolerable events. The effectiveness of the IAC alone is parallel to the IVC alone.
format Online
Article
Text
id pubmed-8485834
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-84858342021-10-22 Application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis You, Chengyu Li, Xianhui Du, Yuelin Wang, Hui Zhang, Xiaojun Wei, Tangqiang Wang, Anguo PeerJ Oncology BACKGROUND: To summarize the current evidence on the effects of intra-arterial chemotherapy (IAC) on high-risk non-muscle invasive bladder cancer (NMIBC) and compare oncology results with intravesical chemotherapy (IVC). METHODS: We performed a systematic review and cumulative meta-analysis of the primary outcomes of interest by a systematical search of multiple scientific databases in February 2021. The mean difference (MD) and odds ratio (OR) were calculated for continuous and dichotomous variables respectively, with 95% confidence intervals (CIs). The hazard radio (HR) with 95% CIs was used for overall survival (OS), recurrence-free survival (RFS) and progression-free survival (PFS). RESULTS: A total of six studies with 866 patients were included. For IAC combined with IVC versus IVC alone, statistically significant differences were found regarding tumor recurrence rate (OR: 0.51, 95% CI [0.36∼0.72], p = 0.0001), tumor progression rate (OR: 0.47, 95% CI [0.30∼0.72], p = 0.0006), tumor-specific death rate (OR: 0.49, 95% CI [0.25∼0.99], p = 0.05), PFS (HR: 0.47, 95% CI [0.23∼0.96], p = 0.04) and RFS (HR: 0.60, 95% CI [0.41∼0.87], p = 0.007). No significant difference between two groups was found for time to first recurrence (MD: 3.27, 95% CI [−2.37∼8.92], p = 0.26) and OS (HR: 1.20, 95% CI [0.44∼3.32], p = 0.72). For IAC alone versus IVC, There was no statistical difference in the terms of tumor-specific death rate (OR: 0.67, 95% CI [0.29∼1.53], p = 0.34), RFS (HR: 0.90, 95% CI [0.56∼1.46], p = 0.68) and PFS (HR: 0.71, 95% CI [0.32∼1.55], p = 0.39). Adverse events mainly included nausea/vomiting (36.3%), hypoleukemia (19.4%), neutropenia (16.0%), increased creatinine (9.9%), increased alanine aminotransferase (18.7%), and thrombocytopenia (9.9%). CONCLUSION: The IAC combined with IVC is a safe and effective treatment for high risk NMIBC, with lower rates of recurrence, progression, tumor-specific death, PFS and RFS, and with minor and tolerable events. The effectiveness of the IAC alone is parallel to the IVC alone. PeerJ Inc. 2021-09-28 /pmc/articles/PMC8485834/ /pubmed/34692255 http://dx.doi.org/10.7717/peerj.12248 Text en ©2021 You et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Oncology
You, Chengyu
Li, Xianhui
Du, Yuelin
Wang, Hui
Zhang, Xiaojun
Wei, Tangqiang
Wang, Anguo
Application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis
title Application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis
title_full Application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis
title_fullStr Application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis
title_full_unstemmed Application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis
title_short Application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis
title_sort application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485834/
https://www.ncbi.nlm.nih.gov/pubmed/34692255
http://dx.doi.org/10.7717/peerj.12248
work_keys_str_mv AT youchengyu applicationofintraarterialchemotherapyinhighrisknonmuscleinvasivebladdercancerasystematicreviewandmetaanalysis
AT lixianhui applicationofintraarterialchemotherapyinhighrisknonmuscleinvasivebladdercancerasystematicreviewandmetaanalysis
AT duyuelin applicationofintraarterialchemotherapyinhighrisknonmuscleinvasivebladdercancerasystematicreviewandmetaanalysis
AT wanghui applicationofintraarterialchemotherapyinhighrisknonmuscleinvasivebladdercancerasystematicreviewandmetaanalysis
AT zhangxiaojun applicationofintraarterialchemotherapyinhighrisknonmuscleinvasivebladdercancerasystematicreviewandmetaanalysis
AT weitangqiang applicationofintraarterialchemotherapyinhighrisknonmuscleinvasivebladdercancerasystematicreviewandmetaanalysis
AT wanganguo applicationofintraarterialchemotherapyinhighrisknonmuscleinvasivebladdercancerasystematicreviewandmetaanalysis